Verition Fund Management
XENT

Verition Fund Management’s Intersect ENT, Inc XENT Stock Holding History

Verition Fund Management’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-34,673
Closed -$971K – 3318
2022
Q1 		$971K Buy
34,673
+7,261
+26% +$199K 0.01% 1488
2021
Q4 		$749K Buy
27,412
+14,061
+105% +$381K 0.01% 1476
2021
Q3 		$363K Buy
+13,351
New +$330K ﹤0.01% 1367
2017
Q3 		– Sell
-11,835
Closed -$331K – 1442
2017
Q2 		$331K Buy
+11,835
New +$268K 0.03% 637

Verition Fund Management's XENT Position: Q2 2022 in Review

Verition Fund Management sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 34,673 shares — an estimated $971K sold.

Verition Fund Management first reported a position in XENT in Q2 2017 and held it in 4 quarters. The position peaked at $971K in Q1 2022. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

  • Verition Fund Management reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
  • Verition Fund Management sold 34,673 Intersect ENT, Inc shares in Q2 2022, an estimated $971K.
  • Verition Fund Management first reported a position in Intersect ENT, Inc in Q2 2017 and held it in 4 quarters.
  • Verition Fund Management's Intersect ENT, Inc position peaked at $971K in Q1 2022.
  • 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on Verition Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.